Edge Capital Group, LLC Gilead Sciences, Inc. Transaction History

Edge Capital Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	SELL	$77.31 - $88.08 $14,920 - $16,999	-193 Reduced 8.52%	2,072 $171,000
Q4 2022 Feb 07, 2023	SELL	$62.32 - $89.47 $3,427 - $4,920	-55 Reduced 2.37%	2,265 $194,000
Q3 2022 Nov 09, 2022	BUY	$59.54 - $68.01 $11,848 - $13,533	199 Added 9.38%	2,320 $143,000
Q2 2022 Aug 08, 2022	BUY	$57.72 - $65.01 $122,424 - $137,886	2,121 New	2,121 $131,000
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $275,885 - $314,358	-4,870 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$62.1 - $78.08 $1.25 Million - $1.57 Million	-20,125 Reduced 80.52%	4,870 $308,000
Q2 2020 Aug 11, 2020	SELL	$72.34 - $84.0 $76,608 - $88,956	-1,059 Reduced 4.06%	24,995 $1.92 Million
Q1 2020 May 08, 2020	BUY	$62.63 - $80.22 $1.63 Million - $2.09 Million	26,054 New	26,054 $1.95 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Edge Capital Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Edge Capital Group, LLC with notifications on news.